These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24289961)

  • 1. Sarcoidosis induced by TNFα antagonists. Comments about the article by Vigne et al. (Joint Bone Spine 2013;80:104-7).
    Toussirot É
    Joint Bone Spine; 2014 Jan; 81(1):105-6. PubMed ID: 24289961
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcoidosis onset during TNFα-antagonist therapy: is infection the culprit?
    Verhoeven F; Prati C; Wendling D
    Joint Bone Spine; 2013 Oct; 80(5):554-5. PubMed ID: 24060397
    [No Abstract]   [Full Text] [Related]  

  • 3. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy.
    Vigne C; Tebib JG; Pacheco Y; Coury F
    Joint Bone Spine; 2013 Jan; 80(1):104-7. PubMed ID: 22885144
    [No Abstract]   [Full Text] [Related]  

  • 4. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
    Miyagi R; Ideguchi H; Soga T; Yamakawa Y; Otsuki H; Niino H; Shiina T; Ueda A; Ishigatsubo Y
    Int J Rheum Dis; 2014 Sep; 17(7):810-2. PubMed ID: 24460777
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic sarcoidosis induced by etanercept: first Brazilian case report.
    Unterstell N; Bressan AL; Serpa LA; Fonseca e Castro PP; Gripp AC
    An Bras Dermatol; 2013; 88(6 Suppl 1):197-9. PubMed ID: 24346918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uveitis associated with sarcoidosis exacerbated by etanercept therapy.
    Suzuki J; Goto H
    Jpn J Ophthalmol; 2009 Jul; 53(4):439-40. PubMed ID: 19763766
    [No Abstract]   [Full Text] [Related]  

  • 8. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
    Hyrich KL; Silman AJ; Watson KD; Symmons DP
    Ann Rheum Dis; 2004 Dec; 63(12):1538-43. PubMed ID: 15242866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis.
    Day R
    Lancet; 2002 Feb; 359(9306):540-1. PubMed ID: 11867103
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple eruptive plaque-like dermatofibromas during anti-TNFα treatment.
    Caldarola G; Bisceglia M; Pellicano R
    Int J Dermatol; 2013 May; 52(5):638-41. PubMed ID: 22804251
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of recurrent pseudoseptic arthritis in a patient with rheumatoid arthritis receiving TNF-alpha blocker.
    Korkmaz C; Kaşifoğlu T
    Joint Bone Spine; 2006 Dec; 73(6):767-8. PubMed ID: 17126056
    [No Abstract]   [Full Text] [Related]  

  • 15. Comments on Falgarone et al. editorial entitled "TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice".
    Legoff P
    Joint Bone Spine; 2008 Oct; 75(5):626; author reply 626. PubMed ID: 18805723
    [No Abstract]   [Full Text] [Related]  

  • 16. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
    Gifre L; Ruiz-Esquide V; Xaubet A; Gómez-Puerta JA; Hernández MV; Sanmartí R
    Arch Bronconeumol; 2011 Apr; 47(4):208-12. PubMed ID: 20638761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of sarcoidosis during etanercept therapy.
    Ishiguro T; Takayanagi N; Kurashima K; Matsushita A; Harasawa K; Yoneda K; Tsuchiya N; Miyahara Y; Yamaguchi S; Yano R; Tokunaga D; Saito H; Ubukata M; Yanagisawa T; Sugita Y; Kawabata Y
    Intern Med; 2008; 47(11):1021-5. PubMed ID: 18520114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.
    Verschueren K; Van Essche E; Verschueren P; Taelman V; Westhovens R
    Clin Rheumatol; 2007 Nov; 26(11):1969-71. PubMed ID: 17340045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.
    Hall HA; Zimmermann B
    Arthritis Rheum; 2006 Dec; 55(6):982-4. PubMed ID: 17139649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.